Please login to the form below

Not currently logged in
Email:
Password:

Sanofi Pasteur begins dengue vaccine study

Sanofi Pasteur, the vaccines division of sanofi-aventis has announced it is to begin a paediatric clinical study to test the efficacy of its tetravalent vaccine for dengue fever

Sanofi Pasteur, the vaccines division of sanofi-aventis has announced it is to begin a paediatric clinical study to test the efficacy of its tetravalent vaccine for dengue fever.

The study will be carried out in Thailand in collaboration with Mahidol University of Thailand, the Ministry of Public Health, and the Paediatric Dengue Vaccine Initiative. The programme follows guidelines from the Initiative for Vaccine Research (IVR) led by the World Health Organisation (WHO).

"Large scale paediatric studies are instrumental for the development of a safe and efficacious dengue vaccine to protect against a disease that primarily affects children," said Dr Pratap Singhasivanon, dean of the faculty of tropical medicine, Mahidol University. "We are happy to contribute to an important milestone with the actual start of an efficacy study in Ratchaburi."

Dengue fever is the most widespread tropical disease after malaria. Carried by mosquitoes, the disease is a threat to almost half of the world's population.

18th February 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...
Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...

Infographics